Edition:
United States

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

8.76USD
18 May 2018
Change (% chg)

$-0.07 (-0.79%)
Prev Close
$8.83
Open
$8.87
Day's High
$8.87
Day's Low
$8.69
Volume
20,366
Avg. Vol
36,895
52-wk High
$36.00
52-wk Low
$7.41

Chart for

About

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $117.82
Shares Outstanding(Mil.): 13.34
Dividend: 10.55
Yield (%): --

Financials

  MACK.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -4.81 -- --
ROI: -307.46 -8.07 12.63
ROE: -- -10.87 14.50

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

May 08 2018

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

Mar 12 2018

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

Feb 26 2018

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

Dec 15 2017

Competitors

Earnings vs. Estimates